Mad Money Uncovered: Merck and the Pharma Laggards
Jim Cramer looks at why he is highlighting pharma along with growth biotech, with Nicole Urken, Mad Money Research Associate.
At the time of publication, Cramer was long ___.
At the time of publication, Cramer was long ___.
